Matsha Tandi E, Kengne Andre P, Masconi Katya L, Yako Yandiswa Y, Erasmus Rajiv T
Department of Biomedical Sciences, Faculty of Health and Wellness Science, Cape Peninsula University of Technology, PO Box 1906, Bellville, Cape Town, 7530, South Africa.
Non-Communicable Diseases Research Unit, South African Medical Research Council & University of Cape Town, Cape Town, South Africa.
BMC Genet. 2015 Jun 26;16:69. doi: 10.1186/s12863-015-0228-6.
The frequencies of apolipoprotein L1 (APOL1) variants and their associations with chronic kidney disease (CKD) vary substantially in populations from Africa. Moreover, available studies have used very small sample sizes to provide reliable estimates of the frequencies of these variants in the general population. We determined the frequency of the two APOL1 risk alleles (G1 and G2) and investigated their association with renal traits in a relatively large sample of mixed-ancestry South Africans. APOL1 risk variants (G1: rs60910145 and rs73885319; G2: rs71785313) were genotyped in 859 African mixed ancestry individuals using allele-specific TaqMan technology. Glomerular filtration rate (eGFR) was estimated using the Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations.
The frequencies of rs73885319, rs60910145 and rs71785313 risk alleles were respectively, 3.6%, 3.4%, and 5.8%, resulting in a 1.01% frequency of the APOL1 two-risk allele (G1:G1 or G1:G2 or G2:G2). The presence of the two-risk allele increased serum creatinine with a corresponding reduction in eGFR (either MDRD or CKD-EPI based). In dominant and log-additive genetic models, significant associations were found between rs71785313 and systolic blood pressure (both p ≤ 0.025), with a significant statistical interaction by diabetes status, p = 0.022, reflecting a negative non-significant effect in nondiabetics and a positive effect in diabetics.
Although the APOL1 variants are not common in the mixed ancestry population of South Africa, the study does provide an indication that APOL1 variants may play a role in conferring an increased risk for renal and cardiovascular risk in this population.
载脂蛋白L1(APOL1)变异体的频率及其与慢性肾脏病(CKD)的关联在非洲人群中差异很大。此外,现有研究使用的样本量非常小,无法为这些变异体在一般人群中的频率提供可靠估计。我们在一个相对较大的混合血统南非人样本中确定了两个APOL1风险等位基因(G1和G2)的频率,并研究了它们与肾脏特征的关联。使用等位基因特异性TaqMan技术对859名非洲混合血统个体的APOL1风险变异体(G1:rs60910145和rs73885319;G2:rs71785313)进行基因分型。使用肾脏疾病饮食改良(MDRD)和慢性肾脏病流行病学协作组(CKD-EPI)方程估算肾小球滤过率(eGFR)。
rs73885319、rs60910145和rs71785313风险等位基因的频率分别为3.6%、3.4%和5.8%,导致APOL1双风险等位基因(G1:G1或G1:G2或G2:G2)的频率为1.01%。双风险等位基因的存在会增加血清肌酐水平,同时相应降低eGFR(基于MDRD或CKD-EPI)。在显性和对数加性遗传模型中,发现rs71785313与收缩压之间存在显著关联(p均≤0.025),糖尿病状态存在显著的统计学交互作用,p = 0.022,反映出在非糖尿病患者中为负向非显著效应,在糖尿病患者中为正向效应。
虽然APOL1变异体在南非混合血统人群中并不常见,但该研究确实表明APOL1变异体可能在增加该人群肾脏和心血管疾病风险方面发挥作用。